

Dear Christopher,

thankyou for the opportunity to comment on the Appraisal consultation document and evaluation report on Cetuximab with radiotherapy in locally advanced head and neck cancer. From my reading of all the evidence submitted, I believe the summary of considerations in the ACD(para 4.11) perfectly describes the current indication for Cetuximab in our clinical practice.

Dr Nick Slevin
Clinical Expert [REDACTED]

Delivered via MessageLabs

The email address [REDACTED] is being phased out and has been replaced with [REDACTED] please amend your records accordingly.

This e-mail and any files transmitted with it are confidential and solely for the use of the intended recipient. If you have received this e-mail in error you should not disseminate, distribute or copy it. Please notify the sender immediately and delete this e-mail from your system.

